Month: February 2024

Company focused on adenosine platform clinical development WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors. The trial is progressing well with eight academic center clinical sites enrolling patients. The Phase 1a dose escalation portion of the trial has progressed to the third cohort. The Company looks forward to making a clinical update at the 2024 American Society of Clinical Oncology...

ADJUSTED EBITDA OF $126 MILLION AND $185 MILLION OF FREE CASH FLOW ENGINEERED SYSTEMS BACKLOG OF $1.5 BILLION PROVIDES SOLID VISIBILITY FOR 2024 REPAID $167 MILLION OF DEBT AND REDUCED NET DEBT-TO-EBITDA RATIO1 TO 2.3 TIMES AT YEAR END CALGARY, Alberta, Feb. 28, 2024 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today reported its financial and operational results for the three months and year ended December 31, 2023. All amounts are presented in Canadian dollars unless otherwise stated. Q4 2023 FINANCIAL AND OPERATIONAL OVERVIEWGenerated revenue of $782 million compared to $778 million in Q3/2023, with results driven by continued strong performance from recurring businesses. Increased gross margin before depreciation and amortization to $216 million, or 27.7% of revenue, compared to...

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent HighlightsTotal revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022Organic revenue was $48.8 million, representing an increase of 1% compared to the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 millionTotal revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023,...

LAVAL, Quebec, Feb. 28, 2024 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces it will release its financial results for the fourth quarter of 2023 after market close on March 6, 2024. Savaria’s management will hold an investor conference call and webcast at 8:30 a.m. Eastern Time (ET) on Thursday, March 7, 2024. Investors and members of the media are invited to participate on a listen-only basis. Conference call access: https://register.vevent.com/register/BI6a2d99af8ce145029a2ec0e3fe3f52d6 To access the conference call, you must register online and choose the method to join the call, either by dialing the number provided to you or by entering your phone number to receive a call from the system. Webcast URL (EN): https://edge.media-server.com/mmc/p/jivftqsd About...

2023 ACCOMPLISHMENTS:Strong results in the high end of Management’s revised outlook range Net revenue up 22% or nearly $2B resulting from strong organic growth of 7.3% and strategic acquisitions Adjusted EBITDA up 26% or nearly $400M Adjusted EBITDA margin at 17.6%, up 55 bps, beyond strategic ambitions of 30 to 50 bps Adjusted net earnings up 24%, resulting from accretive acquisitions and productivity gains Record-high order intake of $15.1 billion, reflecting continued strong market conditions Fourth-quarter net revenue organic growth of 5.1% and robust adjusted EBITDA margin increase of 150 bps Successful consolidation of recent strategic acquisitions substantially completed Strong balance sheet supporting continued growth aspirations Positioned to exceed 2024 strategic financial ambitionsMONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE)...

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended...